The last decade has witnessed a growing use of PET as a clinical tool for the management of patients with cancer, epilepsy, cardiovascular disease, and miscellaneous other disorders. Clearly, PET has made a major impact in oncology where it is used for the diagnosis and staging of a variety of solid tumors and lymphoma.
Third-party payers or national health care policies in Europe, North America, and Australia currently reimburse several clinical applications. In Finland the Turku PET Centre serves as a national provider of health care services associated with the clinical use of PET. Limited services are also available at the University Hospitals of Kuopio, Tampere and Helsinki, by Mobile-PET.
Guidelines for the use of PET for diagnostic applications have recently been published in Finnish and appear as a link to the Finnish part of this web site.